⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Porton Biopharma Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Porton Biopharma Limited
↗Salisbury, United Kingdom
Porton Biopharma Limited (PBL) is a UK-based biopharmaceutical company that was spun out of Public Health England in 2015. It specializes in the development and manufacturing of niche, life-saving biopharmaceuticals and vaccines, including the UK's anthrax vaccine and the leukemia treatment Erwinase®.
Owned by the UK Department of Health and Social Care (DHSC), the company has historically focused on sovereign manufacturing capabilities. However, following a 2025 strategic review, the DHSC announced plans to cease the company's manufacturing operations, leading to a significant shift in its long-term operational status.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2015
Ownership:government
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Vaccines, Therapeutic proteins, Enzymes
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:UK Department of Health and Social Care
Key Partnerships:BlueWillow Biologics (nasal vaccine development)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Mike Austin - CEO
LINKS
Website:portonbiopharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Porton Biopharma Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.